Literature DB >> 11222701

Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences.

Y Guan1, J B Whitney, C Liang, M A Wainberg.   

Abstract

We have constructed a series of simian immunodeficiency virus (SIV) mutants containing deletions within a 97-nucleotide (nt) region of the leader sequence. Deletions in this region markedly decreased the replication capacity in tissue culture, i.e., in both the C8166 and CEMx174 cell lines, as well as in rhesus macaque peripheral blood mononuclear cells. In addition, these deletions adversely affected the packaging of viral genomic RNA into virions, the processing of Gag precursor proteins, and patterns of viral proteins in virions, as assessed by biochemical labeling and polyacrylamide gel electrophoresis. Different levels of attenuation were achieved by varying the size and position of deletions within this 97-nt region, and among a series of constructs that were generated, it was possible to rank in vitro virulence relative to that of wild-type virus. In all of these cases, the most severe impact on viral replication was observed when the deletions that were made were located at the 3' rather than 5' end of the leader region. The potential of viral reversion over protracted periods was investigated by repeated viral passage in CEMx174 cells. The results showed that several of these constructs showed no signs of reversion after more than 6 months in tissue culture. Thus, a series of novel, attenuated SIV constructs have been developed that are significantly impaired in replication capacity yet retain all viral genes. One of these viruses, termed SD4, may be appropriate for study with rhesus macaques, in order to determine whether reversions will occur in vivo and to further study this virus as a candidate for attenuated vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222701      PMCID: PMC115902          DOI: 10.1128/JVI.75.6.2776-2785.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure.

Authors:  G P Harrison; A M Lever
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line.

Authors:  G P Harrison; G Miele; E Hunter; A M Lever
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

4.  Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription.

Authors:  C Liang; X Li; Y Quan; M Laughrea; L Kleiman; J Hiscott; M A Wainberg
Journal:  J Mol Biol       Date:  1997-09-19       Impact factor: 5.469

5.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.

Authors:  J D Lifson; M A Nowak; S Goldstein; J L Rossio; A Kinter; G Vasquez; T A Wiltrout; C Brown; D Schneider; L Wahl; A L Lloyd; J Williams; W R Elkins; A S Fauci; V M Hirsch
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Identification of highly attenuated mutants of simian immunodeficiency virus.

Authors:  R C Desrosiers; J D Lifson; J S Gibbs; S C Czajak; A Y Howe; L O Arthur; R P Johnson
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

Authors:  C A van Baalen; O Pontesilli; R C Huisman; A M Geretti; M R Klein; F de Wolf; F Miedema; R A Gruters; A D Osterhaus
Journal:  J Gen Virol       Date:  1997-08       Impact factor: 3.891

Review 9.  Protective immunity induced by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R C Desrosiers
Journal:  Curr Opin Immunol       Date:  1998-08       Impact factor: 7.486

10.  Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation.

Authors:  J L Clever; T G Parslow
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more
  10 in total

1.  An intact U5-leader stem is important for efficient replication of simian immunodeficiency virus.

Authors:  Y Guan; K Diallo; J B Whitney; C Liang; M A Wainberg
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS.

Authors:  Y Guan; K Diallo; M Detorio; J B Whitney; C Liang; M A Wainberg
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques.

Authors:  Agneta S von Gegerfelt; Vladimir Liska; Pei-Lin Li; Harold M McClure; Kyoji Horie; Filomena Nappi; David C Montefiori; George N Pavlakis; Marta L Marthas; Ruth M Ruprecht; Barbara K Felber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Authors:  Agneta von Gegerfelt; Antonio Valentin; Candido Alicea; Koen K A Van Rompay; Marta L Marthas; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2010-08-11       Impact factor: 5.422

5.  The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.

Authors:  James B Whitney; Maureen Oliveira; Mervi Detorio; Yongjun Guan; Mark A Wainberg
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  The simian immunodeficiency virus 5' untranslated leader sequence plays a role in intracellular viral protein accumulation and in RNA packaging.

Authors:  Jignesh Patel; Shainn-Wei Wang; Elena Izmailova; Anna Aldovini
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.

Authors:  David O Willer; Yongjun Guan; Mark A Luscher; Bing Li; Rick Pilon; Jocelyn Fournier; Monique Parenteau; Mark A Wainberg; Paul Sandstrom; Kelly S MacDonald
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

8.  Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239.

Authors:  James B Whitney; Mark A Wainberg
Journal:  Retrovirology       Date:  2006-12-21       Impact factor: 4.602

9.  Mechanistic differences between HIV-1 and SIV nucleocapsid proteins and cross-species HIV-1 genomic RNA recognition.

Authors:  Klara Post; Erik D Olson; M Nabuan Naufer; Robert J Gorelick; Ioulia Rouzina; Mark C Williams; Karin Musier-Forsyth; Judith G Levin
Journal:  Retrovirology       Date:  2016-12-29       Impact factor: 4.602

10.  Sequences within both the 5' UTR and Gag are required for optimal in vivo packaging and propagation of mouse mammary tumor virus (MMTV) genomic RNA.

Authors:  Farah Mustafa; Dhuha Al Amri; Farah Al Ali; Noor Al Sari; Sarah Al Suwaidi; Preethi Jayanth; Pretty S Philips; Tahir A Rizvi
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.